MARKET WIREYahoo! Finance Canada • 7h ago
Guardant Health, Inc. (GH) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
Why GH Stock dropped -3.51% Today — RQD Quant Desk Flash
$178.80 -3.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $177.33
Guardant Health Inc. (GH) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $24.87B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Guardant Health Inc. (NASDAQ: GH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $178.80 (-3.51% 1D, market cap $24.87B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GH ranks #252 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GH compare to DGX and LH in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), GH carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 64.5%, and ROIC of -17.4%. By comparison, DGX (Quest Diagnostics Incorporated) holds a B+ grade (78/100 RQD, P/E 28.1x, ROIC 10.3%, cap $27.83B) and LH (Labcorp Holdings Inc.) posts a B grade (73/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.86B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GH?
▼
Per GH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576280), Guardant Health Inc. generated $982.0M in revenue (+32.9% YoY), -$416.3M in net income, and -$233.1M in free cash flow against $2.01B in total assets and $950.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $177.33 (-0.82%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GH)Realized 20D OHLCV Swing Band: ±10%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY GH SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (34% of score)
20D Institutional Volume Accumulation (±10% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (21% of score)
Altman Z-Score 5.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$162.09+0.3% Next Q
45
Q2 (-2Q)Grade D$162.59+9.5% Next Q
48
Q3 (-1Q)Grade C-$178.06+0.4% Next Q
50
CurrentGrade D+$178.80-0.9% Hist 90D α
53
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GH Turnaround Squeeze
While GH currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($170.45) and Max Pain ($187.74) forces dealer call-delta covering toward $206.24.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GH Stock dropped -3.51% Today — RQD Quant Desk Flash
Guardant Health Inc. (GH) dropped -3.51% to $178.80, trading at 89% of its 52-week range ($74.55 – $191.05). Stretched risk/reward at current multiples (-17% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 89% of its 52-week range ($74.55 – $191.05) with RSI-14 at 62 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10% around $178.80 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 64.5% gross margin and $0 annual free cash flow.
Live GH Headlines & Catalysts
MARKET WIRETradingKey • 10h ago
Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To KnowTradingKey report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 13h ago
Guardant Health: Growth Remains Too Expensive, Reiterate Hold (NASDAQ:GH)Seeking Alpha report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 16h ago
Guardant Health, Inc. (GH) stock price, news, quote and historyYahoo Finance Singapore report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREFXEmpire • 19h ago
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250FXEmpire report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 22h ago
A blood test in Europe can help identify who may benefit from AstraZeneca’s breast cancer drugStock Titan report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
RISK WATCHFinancialContent • 1d ago
3 Reasons GH is risky and 1 stock to buy insteadFinancialContent report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Guardant Health (GH) Stock Looks Rich Even With Cash Flow UpsideSimply Wall St report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
Illumina Sinks 13% on Light Q3 Revenue Despite EPS Beat and Raised GuidanceKey TakeawaysIllumina shares fell 13% after third-quarter revenue of $1. 13 billion missed consensus, even though adjusted EPS beat and full-year guidance went up.
CATALYSTSeekingAlpha • 4d ago
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take ShareBillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. I rate BLLN stock as Buy.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GH)
- ✓Walkthrough of GH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +96.12%📐 HORIZONTAL RANGE
2026-11-02O $182.6H $185.3L $178.8C $178.8VOL 1.25M
RES: $203.8SUP: $155.0SMA50: $170.5SMA200: $131.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
12.4%/yr Implied 5Y Growth
vs. +32.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GH)
Health Care Rank #252 of 1016
⚔️ DGX vs GH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GH vs. DGX, LH, CNC, ILMN)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Guardant Health Inc. (GH) ranks #252 by composite RQD confidence (53/100, grade D+) and #64 by equity capitalization ($24.87B). Within this direct 5-issuer industry benchmark cohort, DGX leads on earnings valuation at 28.1x trailing P/E, while ILMN leads on capital efficiency and profitability with 18.2% ROIC and 66.1% gross margin. DGX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with GH at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GH
ACTIVE
Guardant Health Inc. | D+ | 53/100 | — | 64.5% | -17.4% | -3.51% | $24.87B | Benchmark Subject |
| DGX Quest Diagnostics Incorporated | B+ | 78/100 | 28.1x | 33.2% | 10.3% | -0.43% | $27.83B | /dgx-vs-gh → |
| LH Labcorp Holdings Inc. | B | 73/100 | 34.0x | 28.8% | 8.3% | -1.84% | $29.86B | /lh-vs-gh → |
| CNC Centene Corporation | C | 63/100 | — | 8.1% | -31.0% | -0.25% | $33.97B | /cnc-vs-gh → |
| ILMN Illumina Inc. | B+ | 77/100 | 51.5x | 66.1% | 18.2% | -18.64% | $43.80B | /ilmn-vs-gh → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001576280In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardant Health Inc. (GH) reported GAAP revenue of $982.0M (+32.9% vs. FY2024 revenue of $739.0M , and +74.1% cumulative change since FY2023) , GAAP net income of -$416.3M, operating cash flow of -$184.8M, and free cash flow of -$233.1M (+15.2% YoY). On the balance sheet, GH closed FY2025 with $2.01B in total assets against $950.8M in total debt (Altman Z-Score: 5.44, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $982.0M | -$416.3M | -$184.8M | -$233.1M | $2.01B | $950.8M |
| FY2024 (FY) | 2024-12-31 | $739.0M | -$436.4M | -$239.9M | -$274.9M | $1.49B | $731.4M |
| FY2023 (FY) | 2023-12-31 | $563.9M | -$479.4M | -$325.0M | -$350.4M | $13.68B | $3.20B |
3. GH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Guardant Health Inc. (NASDAQ: GH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $178.80 (-3.51% 1D, market cap $24.87B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, GH ranks #252 in composite RQD confidence.
How does GH compare to DGX and LH in the Health Care sector?
Within the Health Care sector (Medical Specialities), GH carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 64.5%, and ROIC of -17.4%. By comparison, DGX (Quest Diagnostics Incorporated) holds a B+ grade (78/100 RQD, P/E 28.1x, ROIC 10.3%, cap $27.83B) and LH (Labcorp Holdings Inc.) posts a B grade (73/100 RQD, P/E 34.0x, ROIC 8.3%, cap $29.86B). Among the 5-stock peer group, DGX leads on earnings multiple (28.1x) while ILMN leads on capital efficiency (18.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GH?
Per GH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576280), Guardant Health Inc. generated $982.0M in revenue (+32.9% YoY), -$416.3M in net income, and -$233.1M in free cash flow against $2.01B in total assets and $950.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GH trading relative to its 50-day, 200-day, and 52-week technical levels?
GH last traded at $178.80 (-3.51% on volume of 1,502,593 shares), positioning the stock +4.90% above its 50-day simple moving average ($170.45) and +36.25% above its 200-day simple moving average ($131.23). Across its 52-week range of $74.55 to $191.05, GH sits at the 89.5% percentile with a 14-day RSI of 62.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.0% ($160.92 to $196.68).
GH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GH stock moving today?
Why GH Stock dropped -3.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-17% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 53/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
GH — Guardant Health Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:12:56Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, GH scores 53 out of 100 with a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC -17.4%; FCF yield -0.94%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 6/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 0.87; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 5.44; Piotroski F 6/9; Debt/Equity 0.85). The score is therefore carried mainly by institutional positioning, while the cash-generation and insider pillars are weak. For a prospective investor, the upside driver cited in the data is the institutional flow pillar; the principal valuation tradeoff is that the cash-engine pillar is weak against a forward P/E of 19 and a price of 185.31 near the top of its 52-week range. The forensic pillar indicates a balance sheet the source data characterizes as moderately leveraged with a passing Piotroski profile, but this does not offset negative operating economics. This brief is analytical and educational, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $-437.2M | $-416.3M | N/A | $-233.1M | $378.2M | $950.8M |
| FY 2024 | $739.0M | $-443.6M | $-436.4M | N/A | $-274.9M | $525.5M | $731.4M |
| FY 2023 | $563.9M | $-564.7M | $-479.4M | N/A | $-350.4M | N/A | $3200.5M |
Per the SEC financials, revenue rose from $563.9M (FY 2023) to $982.0M (FY 2025) while operating losses persisted in each period. Market data reports a gross margin of 64.5%, an operating margin of -44.5%, and a net margin of -42.4%. ROIC is -17.4% and FCF yield is -0.94%. Per the Roarable RQD rating forensic pillar, the Altman Z-Score is 5.44 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.85.
Recent Catalysts & News Wire Analysis
- Market wire (Yahoo! Finance Canada, Yahoo Finance Singapore): general market-action and institutional-positioning coverage; no specific event described in the summary text.
- Price action (TradingKey): a report headlined an 8.27% decline on Oct 6 with no further detail in the summary.
- Analyst commentary (Seeking Alpha, tagged CATALYST): headline states "Growth Remains Too Expensive, Reiterate Hold."
- Technical commentary (FXEmpire): headline references a breakout with an upside price path toward $250; summary is generic.
- Clinical/partnership item (Stock Titan): headline describes a blood test in Europe that may help identify patients who may benefit from AstraZeneca's breast cancer drug.
Risk watch items: the Seeking Alpha valuation headline and the reported October decline. Proprietary signals: none listed in the Butterfly Supply-Chain Graph. Per the Butterfly Supply-Chain Graph, supply chain is NONE with no butterfly links.
Open Questions
- What is the P/E (TTM) and EV/EBITDA, given that both are reported as not available in source data while forward P/E is 19?
- What specific drivers account for the FY 2023 debt of $3200.5M falling to $950.8M by FY 2025, and what is the company's debt maturity profile?
- What is the path to positive operating income given reported operating margin of -44.5%?
- Who are the institutional holders and insiders behind the Whale and Insider pillar scores, since the holders section is empty?
- What is the EPS for FY 2025, since the financials list EPS as N/A across all periods?
GH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Guardant Health Inc. (GH) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 7h ago
Guardant Health, Inc. (GH) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 10h ago
Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know TradingKey report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 13h ago
Guardant Health: Growth Remains Too Expensive, Reiterate Hold (NASDAQ:GH) Seeking Alpha report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 16h ago
Guardant Health, Inc. (GH) stock price, news, quote and history Yahoo Finance Singapore report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE FXEmpire • 19h ago
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250 FXEmpire report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 22h ago
A blood test in Europe can help identify who may benefit from AstraZeneca’s breast cancer drug Stock Titan report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH FinancialContent • 1d ago
3 Reasons GH is risky and 1 stock to buy instead FinancialContent report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Guardant Health (GH) Stock Looks Rich Even With Cash Flow Upside Simply Wall St report covering Guardant Health Inc. (GH) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GH Bull vs. Bear Conversation Board — What's Your Call at $178.80?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GH 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $200.13 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is GH (D+ • RQD 53/100) a Buy at $185.31?
Welcome to the GH (Guardant Health Inc.) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $142.69 (-23.0%)
Spot @ $185.31 Pump the brakes on GH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on GH, but look at what you are paying: current EV/EBITDA multiples with 64.5% gross margins. Unless Guardant Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $233.49 (+26.0%)
Spot @ $185.31 GH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on GH, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $185.31 (52-wk range $74.55 - $191.05), any beat on forward guidance forces shorts and underweight funds to chase.